AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 251 min read$OMER

Borges David J. sold $207K of OMER

Borges David J. (VP, Finance & CAO) sold 10,906 shares of OMEROS CORP (OMER) at an average of $18.96 ($18.95–$19.10, $0.21M total) across 2 trades over 2026-08-21 to 2026-08-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Borges David J.
Published Aug 25, 2026, 9:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 9:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$OMER
Neutral
high confidence
Mentioned
$OMER
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMERNeutralLow
01

Why it matters

The transaction is a routine insider divestiture with negligible market impact.

02

Market read

Limited relevance; primarily of interest to existing shareholders monitoring insider activity.

03

What to watch

Potential tax or liquidity motives for the sale; no operational insight.

Relevance 3/10Novelty 4/10Timing: post‑filing on 2026‑08‑25

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates a pre‑arranged sale, often neutral.

Company-level read

Ticker impact

$OMERNeutralHigh confidence
Context

VP of Finance & CAO sold 10,906 shares for $206,805 via a 10b5‑1 plan, reducing his stake to zero.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale size (~$0.2M) is small relative to market cap and was pre‑arranged, indicating no new negative information.

Market effects

Sector

None; insider sale does not affect sector trends.

Regional

None; limited to OMER shareholders.

Global

Minimal; isolated corporate filing.

Counterpoint

What could challenge this read

If the insider had a large unreported stake, the sale could signal concerns, but here the stake was fully liquidated via a plan.

Key entities

  • Officer
    Borges David J.

    Vice President, Finance & Chief Accounting Officer at OMEROS Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

OMER insider trading history →

Related articles

AUG 20
$OMERHighAI 8/10

Omeros (OMER) Q2 2026 Earnings Call Transcript

Omeros (OMER) reported Q2 2026 earnings with Yartemlia gross sales at $32.2M, up 190% from Q1. Net income was $13.2M, including a $11.5M non-cash gain. The company reduced debt by 43% and generated $4.1M in operating cash flow. However, the EMA's committee issued a negative opinion on Yartemlia's marketing authorization application for TA-TMA.

fool.com3 min
AUG 14
$OMERMed

Omeros Corporation Q2 2026 Earnings Call Summary

Omeros reported Q2 2026 progress for Yartemlia, citing 188% quarter-over-quarter net sales growth and $4.1 million positive operating cash flow. Management said adult transplant centers now drive about 75% of sales and formulary approval is 55% to 60%. It also discussed cash flow positivity by mid-2027, repurchases, and regulatory items including a July 1 J-code and Oct. 1 NTAP.

yahoo.com5 min
AUG 13
$OMERHighAI 9/10

Why is Omeros stock surging today?

Omeros (OMER) shares rose about 17% in pre-open after the company reported Q2 2026 results. Adjusted EPS was $0.02 versus a consensus $0.25 loss, and revenue was $28.5M versus $12.67M expected. YARTEMLEA sales were $32.2M gross, and Omeros reported GAAP net income of $13.2M and first positive operating cash flow.

investing.com4 min
AUG 12
$OMERMed

OMEROS CORP (OMER): Results of Operations and Financial Condition

OMEROS CORP (OMER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Omeros Corporation Reports Second Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – August 12, 2026 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second q

SEC EDGAR 8-K7 min
JUL 28
$ENTXMed

Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired

Biotech gainers included Entera Bio (ENTX), up 91% after an oversubscribed private placement expected to raise about $275M. Gossamer Bio (GOSS) rose 47% on plans to file a Seralutinib NDA for PAH in Sept 2026 and regain rights from Chiesi. Forte Biosciences (FBRX) jumped 40% on argenx (ARGX) acquisition for $77/share. Omeros (OMER) gained 16% after AstraZeneca’s Ultomiris failed a Phase 3 endpoint.

rttnews.com6 min